Skip to main content

Table 4 IC50 doses of anticancer drugs in control conditions and after efflux pumps silencing

From: Expression and role of PGP, BCRP, MRP1 and MRP3 in multidrug resistance of canine mammary cancer cells

Anticancer drug

Condition

IC50 in examined cell lines [nmol]

CMT-U27

CMT-U309

P114

CMT-W1

CMT-W2

vinblastine

ctrl

1 588

2 472

2 744

8 072

9 434

pgp siRNA

203***

464***

208***

1 391***

1 264***

bcrp siRNA

1 497

2 417

2 572

8 002

7 346

mrp1 siRNA

144***

772**

756**

1 747***

1 248***

 

mrp3 siRNA

1 330

2 406

2 561

7 433

8 482

cisplatin

ctrl

5 669

12 034

42 944

41 288

9 536

pgp siRNA

2 203**

8 613**

5 000***

32 663***

6 707**

bcrp siRNA

3 300**

8 540**

17 699***

11 228***

8 177*

mrp1 siRNA

1 339**

10 090*

20 348***

29 132***

5 695**

 

mrp3 siRNA

303***

7 301**

13 565***

11 163***

7 177*

cyclophosphamide

ctrl

9 599

12 542

10 340

8 679

25 698

pgp siRNA

8 432

11 755

10 242

7 912

15 443

bcrp siRNA

799***

2 086***

5705**

2 463**

765***

mrp1 siRNA

8 762

11 307

9 955

7 247

7 000

 

mrp3 siRNA

8 802

12 278

10 167

6 932

1 130

  1. IC50 doses [nmol] of anticancer drugs: vinblastine, cisplatin and cyclophosphamide in canine mammary cancer cell lines in control conditions and after silencing of efflux pumps expression. p < 0.05 was marked as *, p < 0.01 was marked as **, and p < 0.001 was marked as ***. One-way ANOVA followed by Tukey HSD post-hoc test was applied.